What Houston Patients Are Actually Paying for GLP-1 Drugs Without Insurance
Open enrollment starts November 1. If you're uninsured in Harris County and wondering whether a GLP-1 drug is financially realistic—or whether an ACA marketplace plan or the Harris Health Gold Card…
Open enrollment starts November 1. If you’re uninsured in Harris County and wondering whether a GLP-1 drug is financially realistic—or whether an ACA marketplace plan or the Harris Health Gold Card would actually change that math—the next few weeks are when the decision has to get made. Here’s what you need to know.
GLP-1 drugs are genuinely expensive. Brand-name monthly costs at Houston retail pharmacies run well over $900 without assistance, depending on the drug and dose. For months, compounded semaglutide at around $150–$350 per month was the practical answer for cash-pay patients. Then the FDA removed semaglutide from the drug shortage list in October 2024, tirzepatide shortly after, and the legal fallout has left the compounding market in active litigation ever since. Whether that cheaper pathway is still open to you depends entirely on which pharmacy you’re calling and under what regulatory authority they’re operating—and that answer is not stable.
This article covers the current legal status of compounding options in Harris County, what the Harris Health Gold Card actually covers for GLP-1s, and what Legacy Community Health and Avenue 360 can offer uninsured patients through federally mandated 340B pricing. Specific pharmacy prices shift frequently. This piece identifies which Houston pharmacies and clinics to call and what questions to ask. No national price aggregator contains this local detail.
The Consultation Fee Nobody Prices Into Their Budget
Every national article on GLP-1 costs starts with the pharmacy. That’s the wrong place to start. Before a pharmacist fills anything, you need a prescription, and getting that prescription as an uninsured patient in Houston is its own cost layer—one most people don’t see coming until they’re already in the waiting room.
Initial uninsured consultations at Houston obesity medicine clinics generally run somewhere between $150 and $350 for a new patient visit, with monthly follow-ups stacked on top. Call each clinic directly to confirm current self-pay rates.
UTHealth Houston Obesity Medicine is part of the McGovern Medical School system and offers physician-level obesity medicine care. The advantage is continuity: you’re seeing a board-certified physician who can coordinate with your primary care if side effects emerge. Call UT Physicians scheduling and ask specifically for the new patient uninsured cash price before booking.
Baylor Medicine Weight Management, affiliated with Baylor College of Medicine, operates out of the McNair Campus near the Medical Center. Their program is structured around metabolic evaluation, which typically means they want labs before prescribing—another cost layer for uninsured patients paying cash. Call to confirm self-pay rates for both the consultation and any required labs upfront.
Cingulum Health is a Houston-based telehealth-forward obesity medicine practice that has moved aggressively into the GLP-1 space with a simplified video-visit model. The physicians include board-certified clinicians, but that care model may not suit patients with complex metabolic histories or multiple comorbidities who’d benefit from in-person testing. Contact Cingulum directly to confirm current self-pay consultation and monthly follow-up fees.
Then there’s the medspa tier, concentrated in River Oaks, Montrose, and Midtown. These clinics operate under medical director supervision—with nurse practitioners or physician assistants doing the actual prescribing—and often offer lower entry-cost GLP-1 programs, frequently bundling compounded semaglutide into a monthly package. Operating under Texas Medical Board rules, this is legal. But the practical concern isn’t legality. It’s what happens if your prescribing NP leaves, or the clinic closes. Your prescription history doesn’t follow you to a hospital system the way it would from UTHealth or Baylor. For patients managing hypertension, sleep apnea, or Type 2 diabetes alongside obesity, that’s not a minor inconvenience—it’s a genuine clinical gap. The medspa model can work for otherwise healthy patients who want a simple, affordable entry point. It’s a worse fit for anyone with complicated metabolic history, and those are often the exact patients most likely to need this drug.
Monthly follow-up costs are the budget line most patients miss. At every clinic model, you’re paying a recurring visit or membership fee on top of your drug cost. Get that number explicitly before committing. No exceptions.
Brand-Name Prices at Houston Pharmacies: Where to Call
Pharmacy cash prices for brand-name GLP-1s are set by manufacturers and shift with coupon availability. National list prices as of early 2025 ran approximately $900–$1,000 per month for Ozempic (semaglutide, diabetes-indicated), around $1,350 per month for Wegovy (semaglutide, obesity-indicated), $1,000–$1,100 per month for Mounjaro (tirzepatide, diabetes-indicated), and roughly $1,050 per month for Zepbound (tirzepatide, obesity-indicated). These are manufacturer list prices, not Houston-specific cash or coupon pricing. Call directly for current figures before making a budget decision.
H-E-B Pharmacy operates multiple Houston locations worth calling: the Buffalo Speedway location near the Medical Center, Bunker Hill in West Houston, and 610/Shepherd in Heights/Montrose. Ask for the cash price at the starting titration dose and the maintenance dose separately—cost changes as the dose increases, and most cost comparisons you’ll find online use a single price point that understates long-term expenses. Ask specifically whether GoodRx is accepted and what that adjusted price is.
CVS locations at Greenway Plaza and near the Medical Center can quote cash prices for Ozempic (0.5mg and 1mg), Wegovy, Mounjaro (2.5mg and higher doses), and Zepbound. Ask for both cash and GoodRx-adjusted pricing.
Costco Pharmacy at the Katy Freeway/I-10 West or Westheimer locations runs a lower-margin model that typically comes in below CVS on brand-name drugs. Worth knowing: Costco’s pharmacy is open to non-members for prescription fills in Texas. That’s not nothing when you’re trying to squeeze every dollar out of this math.
At these list prices, you’re looking at over $900 per month for the least expensive brand-name option and over $1,300 for Wegovy. For most uninsured Houstonians, that’s not a sustainable cash-pay option. The national coverage tends to float past that number. It’s worth sitting with it.
The Compounding Question and What’s Actually Still Legal Here
This is where it gets genuinely complicated, and it’s where the decision gets hardest.
The FDA added semaglutide and tirzepatide to its drug shortage list during the supply crunch before 2024. That designation opened a legal window for compounding pharmacies—both 503A retail compounders and 503B outsourcing facilities—to produce copies without running afoul of the prohibition on compounding commercially available products. Compounded semaglutide at $150–$350 per month became the affordable answer for millions of uninsured and underinsured patients. In Harris County, it was a real lifeline.
The FDA officially removed semaglutide from the shortage list in October 2024, tirzepatide shortly after. That triggered a legal obligation for compounders to stop production. The FDA set enforcement deadlines, compounders challenged in federal court, courts issued temporary relief. 503A pharmacies—traditional retail compounders—faced earlier and more aggressive enforcement. 503B outsourcing facilities, which are FDA-registered and subject to current Good Manufacturing Practice standards, got separate, extended deadlines and operate under stricter oversight. Multiple lawsuits from compounding industry groups were still active into 2025.
Empower Pharmacy is headquartered in Houston and is one of the largest 503B outsourcing facilities in the country—a Houston company sitting at the center of a national regulatory fight. Whether Empower is currently authorized to compound these drugs requires a direct call and confirmation of current FDA compliance status. The regulatory ground has shifted repeatedly. Empower doesn’t sell directly to patients; access runs through a prescribing physician and clinic or telehealth partners.
Village Compounding Pharmacy in Katy and Woodlands Compounding Pharmacy in the north Houston suburbs are traditional compounding pharmacies whose status has been subject to FDA enforcement actions targeting 503A-type facilities. Call both directly. Ask whether they’re currently compounding semaglutide or tirzepatide for new patients, under what regulatory basis, and get that confirmation before relying on them.
For patients evaluating compounded options: ask any clinic or pharmacy offering compounded semaglutide which specific facility is producing it. Confirm it’s a licensed 503B outsourcing facility operating with current FDA authorization. The regulatory situation remains in active litigation. The Texas State Board of Pharmacy (512-305-8000) can answer state-level questions for Texas-licensed compounders. If a medspa or telehealth clinic is offering compounded semaglutide at a steep discount, ask those questions before committing. The price is attractive. The uncertainty is real, and it’s not resolving quickly.
The Harris Health Gold Card: What It Actually Covers
The Harris Health Gold Card is Harris County’s low-income healthcare access program for residents who don’t qualify for Medicaid and can’t afford private insurance. Eligibility is based on Harris County residency and income at or below 200% of the federal poverty level for most tiers. Texas didn’t expand Medicaid under the ACA, which means a large population falls into a coverage gap and pays cash for prescriptions. Harris Health runs Ben Taub Hospital, Lyndon B. Johnson Hospital, and a network of community health centers.
The central question for GLP-1 drugs is whether the Gold Card formulary covers the diabetes indication, the obesity indication, or both. These are distinct FDA approvals, and the distinction matters more than most patients realize until they’re at a pharmacy counter. Ozempic and Mounjaro are approved for Type 2 diabetes management. Wegovy and Zepbound are approved for chronic weight management. Publicly funded formularies frequently cover the diabetes indication while excluding the obesity-only indication because of cost. That’s not hypothetical—it’s a common formulary structure in programs like this.
Call Harris Health Pharmacy Benefits at (713) 566-6400 and ask: Is semaglutide on the Gold Card formulary, and for which diagnosis codes? Is tirzepatide covered, and under what conditions? What is the patient cost-share at the lowest income tiers? Is prior authorization required? Can GLP-1 prescriptions for the diabetes indication be initiated at a Harris Health community health center, or only through Ben Taub or LBJ specialty services?
If the Gold Card covers semaglutide for the diabetes indication, that’s meaningful access for diabetic patients at income-based cost-share well below retail. For patients seeking GLP-1 treatment for obesity alone, without a diabetes diagnosis, the formulary structure may simply not provide a pathway. Get the current formulary answer directly from Harris Health. Don’t assume coverage until you’ve heard it confirmed.
The FQHC Pathway: Legacy, Avenue 360, and 340B Pricing
Federally Qualified Health Centers receive federal funding tied to two benefits for uninsured patients: a mandated sliding-scale fee schedule for clinic visits based on income, and eligibility for the federal 340B drug pricing program, which lets FQHCs purchase drugs from manufacturers at deeply discounted rates. In theory, 340B savings on a drug like Wegovy—over $1,300 at retail—could reduce patient cost substantially. Whether those savings actually get passed through to patients varies by institution. FQHCs may not stock high-cost GLP-1s at all due to cost and operational complexity. Call before building any financial plan around this.
Legacy Community Health operates more than 50 sites across Harris County and is Houston’s largest FQHC. Their clinical service lines include diabetes management and primary care, where providers prescribe GLP-1 drugs, primarily semaglutide for Type 2 diabetes management. Legacy participates in 340B. Whether those savings are passed through to patients on GLP-1s specifically—rather than used to subsidize the institution’s operating costs, which is a permissible use of 340B savings—requires a direct conversation. As part of our health & wellness coverage, we’ll continue tracking how Houston’s safety-net providers handle formulary access for high-cost drugs.
Call Legacy Community Health at (832) 548-5000 and ask for pharmacy director or clinical pharmacy services. Ask whether Legacy prescribes GLP-1s for obesity indications as well as diabetes, what the sliding-scale fee is for an uninsured new patient visit, and whether uninsured patients filling semaglutide at a Legacy dispensing pharmacy receive 340B pricing—and approximately what it costs.
Avenue 360 Health and Wellness, with clinic sites in Midtown and Montrose, is another major Harris County FQHC participating in 340B with sliding-scale fees for uninsured patients. Call (713) 830-3000 to confirm whether their primary care providers prescribe GLP-1s and what the uninsured patient cost structure looks like.
El Centro de Corazón is an East Houston FQHC serving a predominantly Latino patient population, and it’s worth naming directly. Harris County’s Latino residents carry some of the highest rates of Type 2 diabetes in the region—a direct driver of why GLP-1 access matters specifically in that community. El Centro’s clinical model is built around chronic disease management in a population that’s disproportionately uninsured. Their providers prescribe semaglutide for diabetes management, and their sliding-scale fees are comparable to other Harris County FQHCs. For East Houston patients, El Centro is likely the most geographically accessible entry point into a GLP-1 prescription pathway connected to subsidized pricing.
The FQHC pathway takes longer than a medspa appointment and requires income documentation. It’s not frictionless. But it’s legally stable in ways the compounding pathway currently isn’t, and for patients who qualify, it’s probably the most durable long-term option. The limitation is real: access is clearest for patients with Type 2 diabetes or documented cardiovascular risk. Obesity alone may not be enough to open the door.
Manufacturer Assistance Programs: Real, But Not Fast
Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) both operate Patient Assistance Programs separate from their commercial savings cards. The savings cards require commercial insurance and don’t work for uninsured patients—Houston pharmacies have confirmed this, so don’t walk into a CVS counting on the coupon you saw advertised. The Patient Assistance Programs for the uninsured are different programs, and they’re worth pursuing.
Novo Nordisk’s NovoCare program and Eli Lilly’s Lilly Cares Foundation both offer drug assistance for uninsured patients who meet income and eligibility requirements. Applications require a completed form from a prescribing physician, proof of income, and a current prescription. Call each program directly to confirm current income thresholds and application timelines before treating this as an immediate solution.
Here’s the friction that catches people: you can’t access either program without a prescribing physician already in your care. The consultation cost is unavoidable—you need the physician relationship to submit the application. Patients who’ve gone through this process report that it works and the drugs do arrive, but there’s a meaningful wait between application and first delivery. This is a medium-term solution, not an emergency one. Plan accordingly.
One concrete step worth knowing: if you’re a Legacy Community Health patient, ask at intake whether a social work referral is available to assist with pharmaceutical assistance program applications. FQHCs typically have patient advocates trained to navigate exactly this, and most patients don’t think to ask.
Four Real Paths, Ranked by Monthly Out-of-Pocket Cost
This is a structural comparison, as of the current reporting period, of the available pathways for a Harris County uninsured patient seeking semaglutide. Call named providers directly to confirm current pricing—these numbers move.
Path 1: Brand-name at full retail cash price. Ozempic runs above $900 per month; Wegovy runs above $1,300—before the monthly clinic follow-up. Call H-E-B, CVS, and the Costco locations listed above for current Houston cash prices. Access is straightforward. It’s financially realistic only for patients with significant disposable income or bridging a short gap before coverage starts.
Path 2: Brand-name with GoodRx adjustment. A real but modest reduction from list price at CVS or Costco. Costco typically runs below CVS on brand-name drugs. Call to confirm current GoodRx-adjusted pricing at each location before assuming savings, and confirm GoodRx acceptance at the counter before you’re standing there.
Path 3: Compounded semaglutide through a 503B clinic pathway. Historically available in the $150–$350 range through prescribing clinic partners working with 503B outsourcing facilities such as Empower Pharmacy. Current pricing and availability require direct confirmation—regulatory conditions have changed materially since 2024 and continue to shift. Ask explicitly which 503B facility is supplying any compounded medication before relying on this option. The legal ground is moving.
Path 4: FQHC sliding-scale pathway through Legacy, Avenue 360, or El Centro. Works with 340B pricing to potentially reduce drug costs well below retail for eligible patients filling through an FQHC dispensing pharmacy. Sliding-scale visit fees are income-based and federally mandated. Call Legacy at (832) 548-5000 and Avenue 360 at (713) 830-3000 to confirm current drug pricing under 340B and visit fee schedules for uninsured patients. Federally mandated programs aren’t subject to FDA compounding enforcement, which matters right now. The primary limitation is the diabetes/obesity indication gap. Income documentation is required. Not the fastest path—but the most stable one currently available.
Open Enrollment Math: ACA Marketplace or the Gold Card?
For uninsured Harris County residents making this decision now, here’s the framework.
The Gold Card makes the most sense if your income is at or below 200% of the federal poverty level, you’re a Harris County resident, and you have a Type 2 diabetes diagnosis or significant metabolic risk that would justify a GLP-1 prescription on the diabetes indication. You get subsidized care at Harris Health facilities and potential Ozempic access through the formulary at income-based cost-share well below retail. No monthly premium. Call Harris Health to confirm current formulary terms before counting on this.
ACA Marketplace plans make more sense if your income qualifies for premium tax credits. But there’s a trap that catches a lot of people: not all ACA marketplace plans cover GLP-1 drugs for the obesity indication. Many cover Ozempic and Mounjaro for diabetes while specifically excluding Wegovy and Zepbound. Before enrolling, check the specific plan’s formulary—not just whether the plan covers “GLP-1s” as a category—and confirm whether obesity-indicated prescribing is a covered benefit. This information is available through the plan comparison tool at HealthCare.gov under drug coverage, or by calling the insurer’s pharmacy benefits line directly with the plan ID in hand. Do this before you enroll.
For patients who need a GLP-1 for weight management without a diabetes diagnosis—and whose income is too high for the Gold Card but nowhere near enough to absorb full retail pricing—an ACA plan that explicitly covers Wegovy or Zepbound may be the only path to sustainable access. That coverage varies by plan and isn’t guaranteed even at higher premium tiers. Check the formulary. It matters more than the premium.
The coverage gap Texas’s Medicaid non-expansion created sits directly on the demographic that most needs GLP-1 support. Harris County has historically seen more than 20% of adults uninsured—one of the highest rates of any major U.S. city. Looking at a $1,300 monthly drug price against that backdrop is uncomfortable. The compounding pathway was, for that population, a genuine partial answer. Its current legal uncertainty makes the FQHC route more important than it’s been in years.
The Gold Card accepts applications year-round at Harris Health community health centers. Check current ACA marketplace open enrollment deadlines and coverage start dates at HealthCare.gov. For patients who are also navigating other gaps in coverage—dental care is a common one for people in this income band—our guide to free and low-cost dental care for Houston adults covers similar safety-net options in Harris County.
Program details and regulatory status were current as of the reporting period. Drug pricing, formulary coverage, and compounding regulatory status change frequently. Verify current pricing and program availability directly with named providers before making financial or healthcare decisions. Key contacts: Harris Health Pharmacy Benefits (713) 566-6400; Legacy Community Health (832) 548-5000; Avenue 360 Health and Wellness (713) 830-3000; Texas State Board of Pharmacy (512) 305-8000.
